Last updated 2026-06-18
- Went public, May 2021
- Raised $25M funding round, Jan 2022
- Raised $16M funding round, Aug 2024
Total raised
$176.2M
Last: 2024-08
Stage
Public
Founded
2014
Headcount
14
HQ
Haifa, Israel
Sector
Health Tech & Life Sciences
About
NeuroRX is a specialized CNS biopharma company, resolutely focused on meeting very high unmet medical needs for those with severe bipolar depression with suicidality and post-traumatic stress disorder (PTSD).
The company growing pipeline is powered by its proprietary, dual-targeted mechanism of action, which safely modulates the NMDA and 5HT2A receptors. Its mission is to bring hope to people with life-threatening diseases through breakthrough science.
Funding history · 5 rounds · $176.2M total
2024-08
$16.0M
2024-03
$2.9M
2023-06
$6.3M
2022-11
$11.0M
2022-01
$25.0M
Q&A
- What was the most recent funding round for NRx Pharmaceuticals?
- NRx Pharmaceuticals completed a funding round in August 2024, raising $16,000,000.
- What was the most recent public offering by NRx Pharmaceuticals?
- In April 2024, NRx Pharmaceuticals had a public offering on NASDAQ, raising $2,000,000.
- What is the primary focus of NRx Pharmaceuticals?
- NRx Pharmaceuticals is a specialized CNS biopharma company focused on meeting unmet medical needs for severe bipolar depression with suicidality and post-traumatic stress disorder (PTSD).
- How many employees does NRx Pharmaceuticals have?
- NRx Pharmaceuticals has 11-50 employees.
- When did NRx Pharmaceuticals go public?
- NRx Pharmaceuticals went public on NASDAQ in May 2021, with a valuation of $1,500,000,000 through a SPAC merger with Big Rock Partners Acquisition Corporation.
- What is the current market capitalization of NRx Pharmaceuticals?
- The current market capitalization of NRx Pharmaceuticals is $80,229,957.
- What is NRX-101 being developed for?
- NRX-101 is being developed for the treatment of chronic pain, with NRx Pharmaceuticals announcing FDA permission to proceed on an Investigational New Drug (IND) application in October 2023.
- What recent acquisition did HOPE Therapeutics, an NRx Pharmaceuticals subsidiary, complete?
- In September 2025, HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, completed the acquisition of Dura Medical, marking an initial acquisition in its network of interventional psychiatry clinics.
Team · 2
Daniel C. Javitt, Prof., M.D., Ph.D
Founder · Chairman & Co-Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesHealthcarePatientsProviders
Business model
B2B
Highlights
1 PatentsVerified
Tags
mental-healthpsychiatrypharmaceuticalsschizophreniachronic-pain
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | nrxpharma.com/ |
|---|---|
| linkedin.com/company/10024731 | |
| facebook.com/NRxPharma |
Identifiers & details
| Founded | 2014-10 |
|---|---|
| Employees (exact) | 14 |
| Offices | Wilmington |
| Market cap | $80.2M |
| Status reason | Public on NASDAQ on May, 2021 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2024-04 | $2.0M | |||
| 2021-05 | $140.0M |